All In MedTech

FDA Clearance Tracker · P220032-S006

POLARx/POLARx FIT Cryoablation Catheters, SMARTFREEZE Cryoablation Console, Accessories

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 5, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 5, 2024

Approved

Time to decision

30 days

Received Jun 5, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P220032-S006
Device name
POLARx/POLARx FIT Cryoablation Catheters, SMARTFREEZE Cryoablation Console, Accessories
Applicant location
St Paul, MN
Received
Jun 5, 2024
Decided
Jul 5, 2024
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P220032

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

approval of the revised protocol (Version F) for the post-approval study (PAS) protocol submitted to comply with the conditions of approval outlined in our approval order for P220023

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.